cvs health glp-1 receptor agonist weight management diabetes treatments Caremark expands access to drugs Stopping GLP-1s: What We Know

Additionally, tirzepatide significantly improved hypoxic burden, lowered C-reactive protein (CRP), and reduced systolic blood pressure, underscoring its broad cardiometabolic benefits

J., Stubbs, B., Mamas, M

Grunvald E., Shah R., Hernaez R., et al., AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity, Gastroenterology 163 (2022): 11981225

With the increasing popularity of this topic, and the use of these drugs, we will continue to stay informed to ensure we are providing the best services to our clients

A recent meta-analysis including data from SURMOUNT-1, a trial conducted in individuals with obesity, confirmed the favorable effects of tirzepatide on dyslipidemia, finding a 16 and 13.7% change from baseline in triglycerides and very low-density lipoproteins with tirzepatide 15 mg vs

The progressive form, MASH, exhibits hepatocyte damage, inflammatory cell infiltration, and variable degrees of tissue fibrosis, with advanced fibrosis representing the predominant prognostic determinant for hepatic morbidity and mortality, as well as an additional risk factor for extrahepatic complications